SkinPen® Precision Wins 2021 Aesthetic Award for Best Non-Surgical Technology in the Industry

DALLAS, 12 October 2021 / PRNewswire / – Crown aesthetics, a division of Crown Laboratories and the world leader in microneedling technology, is proud to announce that SkinPen Precision has once again been recognized as one of the best in the industry for its superior innovation and technology. Presented by The Aesthetic Guide, the Aesthetics price Shine the spotlight on the product manufacturers and practice management companies that are shaping the future of aesthetic medicine.

Crown Laboratories (PRNewsfoto / Bellus Medical, a division of Crown Laboratories)

SkinPen Precision is the first FDA approved microneedling device on the market. In United States, SkinPen is clinically proven to improve the appearance of neck wrinkles for Fitzpatrick II – IV skin types and to improve the appearance of facial acne scars in adults with all skin types Fitzpatrick aged 22 years and more. In the EU, SkinPen is also intended to treat pigmentation problems (dyschromia), including melasma, vitiligo and solar lentigines. The indications for SkinPen Precision may vary depending on the country.

SkinPen has passed over 90 validated tests to set the standard for microneedling. SkinPen’s handpiece is ergonomically designed based on user feedback and is ultrasonically sealed for easy cleaning and increased patient safety. The superior cartridge design of SkinPen prevents the entry of fluids into the device which, along with the bio sheath and routine cleaning, helps prevent potential cross contamination. The patented cartridge features proprietary technology that includes 14 stainless steel needles that have been validated to stay sharp for at least 80 minutes. With patient safety a priority, the single use locking feature eliminates the possibility of dual use and cross contamination. This safe and versatile treatment can be performed on patients all year round.

“Crown Aesthetics is delighted to be honored with this award from The Aesthetic Guide,” said Joe proctor, president of Crown Aesthetics. “We are proud to be at the forefront of today’s aesthetic treatment market by providing the best medical technologies that are effective and safe for both practices and patients. Crown Aesthetics is a company that sets industry standards for efficiency, safety and innovation, which enables our dedicated partners to consistently deliver the best aesthetic care in the industry. It’s great to be recognized as an industry leader.

About the aesthetics of the crown
Crown Aesthetics, the premier medical aesthetic company, is dedicated to helping leading aesthetic practices around the world grow their businesses. We do this by providing spectacular results in rejuvenation and restoration. Our non-invasive innovations – SkinPen®, the first FDA-approved microneedling device; the Skinfuse® post-microneedling protocol; and the ProGen Advantage Platelet Rich Plasma (PRP) System – act as “gateway” products that attract new consumers to the practices. Situated at Dallas, Texas, Crown Aesthetics sets the industry standard for efficiency, safety and innovation. As a result, our customers consistently provide the best aesthetic care in the industry. For more information, please visit

About Crown Laboratories, Inc.
Crown, a private and fully integrated global skin care company, is committed to developing and delivering a diverse portfolio of aesthetic, premium and therapeutic skin care products that enhance the quality of life of its consumers throughout. throughout their skin care journey. An innovative company focused on the science of skin for life, Crown’s unwavering pursuit of delivering therapeutic excellence and improving patient outcomes is why it has become a leader in dermatology and aesthetics. Crown is on Inc.’s list of the 5,000 fastest growing private companies in eight years and has expanded its distribution to more than 38 countries. For more information visit



View original content to download multimedia:

SOURCE Crown Laboratories, Inc.

Source link

Comments are closed.